A Phase 3 interventional study of Ixabepilone + Capecitabine and Capecitabine in Cancer and Breast Cancer, sponsored by R-Pharm. Completed at 189 sites in 29 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-02.
Sponsored by R-Pharm · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies testing ixabepilone in Breast Neoplasms — none open to participants now, 1 under way, none of them phase 3. ixabepilone · Breast Neoplasms.
Among the 41 studies testing ixabepilone in Breast Neoplasms, this one has the largest enrollment of the 39 interventional ones that give a count, is one of 2 that started in 2003, is one of 5 in phase 3, and was the 8th registered.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
Browse Breast Neoplasms studies →None of the 41 studies testing ixabepilone in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
ixabepilone: first FDA approval 2007 (IXEMPRA KIT). What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,573 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 29 · Phase 3 5
First in 2000; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,221 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Median enrollment 56 across the 39 interventional studies. Of the 38 that completed or were terminated, 28 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 41 have an industry lead sponsor. The 10 most frequent:
R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
15 studies in Breast Neoplasms by R-Pharm: none open now, 1 under way, 1 of them phase 3. Of 13 finished, 10 (77%) have results posted.
Among the 15 studies in Breast Neoplasms by R-Pharm, this one has the largest enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2003, is one of 3 in phase 3, and was the 4th registered.
R-Pharm’s Breast Neoplasms studies by the year they started, since 2002.
1 of the studies testing ixabepilone in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00877500M.D. Anderson Cancer CenterIxabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies testing ixabepilone in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among R-Pharm’s 15 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.
14,843 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.
This study's enrollment of 1,221 is above the median of 72 across 10,911 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.
Compared within Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Ixabepilone + Capecitabine
Drug: Capecitabine
Drug pages: Ixabepilone · Capecitabine
Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
Also known as: IXEMPRA®, Epothilone
Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
Overall Survival (OS)
Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.
Time frame: from date of randomization until death
Progression-Free Survival (PFS)
PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.
Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Response Rate (RR)
RR=number of patients in that group whose best response is "partial"(30% decrease in the sum of the longest diameter of target lesions) or "complete" (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants
Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Duration of Response
Measured from the time RECIST criteria (described in previous outcome measure) were first met for "complete" or "partial" response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.
Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Time to Response
Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for "partial" or "complete" (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).
Time frame: every 6 weeks (± 3 days) from randomization while on treatment until documented progression
Treatment-Related Safety Summary
Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0
Time frame: safety was assessed on a continual basis every cycle while on-treatment and every 4 weeks post treatment until toxicities resolved or were deemed irreversible.
Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)
Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.
Time frame: Baseline and prior to each 21-day cycle of treatment, and at first posttreatment follow-up assessment
| Milestone | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Started | 609 | 612 |
| Completed | 15 | 15 |
| Not completed | 594 | 597 |
| Withdrew: Adverse event | 12 | 17 |
| Withdrew: Death | 8 | 18 |
| Withdrew: Disease progression/relapse | 270 | 388 |
| Withdrew: Physician decision | 50 | 61 |
| Withdrew: Lost to follow-up | 1 | 2 |
| Withdrew: Study drug toxicity | 179 | 66 |
| Withdrew: Withdrawal by subject | 55 | 30 |
| Withdrew: Still on treatment | 2 | 1 |
| Withdrew: Not treated | 12 | 11 |
| Withdrew: Ineligible | 2 | 1 |
| Withdrew: Noncompliance | 2 | 1 |
| Withdrew: New primary cancer | 1 | 0 |
| Withdrew: Impending surgery | 0 | 1 |
PFS was defined for each patient as the time in months from randomization to the date of progression. Patients who died without a reported prior progression were considered to have progressed on their date of death. Patients who did not progress or die were censored on the date of their last tumor assessment.
| months | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Progression-Free Survival (PFS) | 6.24 (5.59 to 6.77) | 4.40 (4.14 to 5.42) |
RR=number of patients in that group whose best response is "partial"(30% decrease in the sum of the longest diameter of target lesions) or "complete" (disappearance of all target lesions), according to the 4-item Response Evaluation Criteria in Solid Tumors (RECIST), divided by the total number of response-evaluable participants
| percentage of participants | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Response Rate (RR) | 43.3 (38.7 to 47.9) | 28.8 (24.7 to 33.2) |
Measured from the time RECIST criteria (described in previous outcome measure) were first met for "complete" or "partial" response until first date of documented disease progression or death. Patients who neither relapsed nor died were censored on the date of last tumor assessment. Median w/ 95% CI estimated using Kaplan Meier Product Limit Method.
| Months | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Duration of Response | 6.1 (5.5 to 7.0) | 6.3 (5.3 to 7.6) |
Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for "partial" or "complete" (whichever status was recorded first) per RECIST criteria (a 4-item scale described in the previous outcome measure).
| weeks | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Time to Response | 6.6 (4.7 to 47.9) | 6.6 (4.6 to 59.4) |
Laboratory values, adverse events, and other symptoms were graded using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTC) Version 3.0
| Participants | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Deaths within 30 days of last dose | 19 | 42 |
| Treatment-related serious adverse events | 125 | 64 |
| Treatment-related Grade 3-4 adverse events | 458 | 240 |
| Treatment-related AEs leading to discontinuation | 286 | 66 |
Quality of life, as measured by the FBSI, an 8-item, participant-reported instrument to measure symptoms. Each item has 5 possible responses ranging from 0 (not at all) to 4 (very much). The scoring was conducted according to the Functional Assessment of Chronic Illness Therapy manual, Version 4; higher scores reflect fewer symptoms.
| units on a scale | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Week 3 (n=440; n=429) | -0.5 ± 13.7 | 0.0 ± 4.7 |
| Week 6 (n=379; n=353) | -0.9 ± 15.4 | 0.5 ± 5.0 |
| Week 9 (n=330; n=283) | -1.5 ± 17.4 | 0.7 ± 5.0 |
| Week 12 (n=283; n=250) | -1.4 ± 17.3 | 1.1 ± 5.2 |
| Week 15 (n=255; n=240) | -1.9 ± 17.0 | 1.5 ± 5.0 |
| Week 18 (n=205; n=202) | -1.3 ± 15.7 | 1.2 ± 5.4 |
| Week 21 (n=166; n=185) | -1.4 ± 16.8 | 1.7 ± 5.1 |
| Week 24 (n=149; n=141) | -1.4 ± 17.3 | 1.1 ± 5.4 |
Overall survival was defined as the time in months from randomization until the date of death. For those patients who had not died, survival duration was censored at the last date the patient was known to be alive. Median OS with 95% CI estimated using the Kaplan-Meier Product Limit Method.
| months | Ixabepilone + Capecitabine | Capecitabine |
|---|---|---|
| Overall Survival (OS) | 16.39 (14.95 to 17.91) | 15.64 (13.86 to 17.02) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine | — | 192/603 (31.8%) | 564/603 (93.5%) |
| Ixabepilone + Capecitabine | — | 205/595 (34.5%) | 590/595 (99.2%) |
| Event | Capecitabine | Ixabepilone + Capecitabine |
|---|---|---|
| MALIGNANT NEOPLASM PROGRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 43/603 | 17/595 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 5/603 | 34/595 |
| DIARRHOEAGastrointestinal disorders | 33/603 | 23/595 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 25/603 | 10/595 |
| VOMITINGGastrointestinal disorders | 17/603 | 24/595 |
| NEUTROPENIABlood and lymphatic system disorders | 8/603 | 18/595 |
| PLEURAL EFFUSIONRespiratory, thoracic and mediastinal disorders | 13/603 | 7/595 |
| NAUSEAGastrointestinal disorders | 7/603 | 12/595 |
| MALIGNANT PLEURAL EFFUSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/603 | 5/595 |
| LEUKOPENIABlood and lymphatic system disorders | 1/603 | 8/595 |
| Event | Capecitabine | Ixabepilone + Capecitabine |
|---|---|---|
| PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROMESkin and subcutaneous tissue disorders | 412/603 | 383/595 |
| NAUSEAGastrointestinal disorders | 243/603 | 315/595 |
| FATIGUEGeneral disorders | 166/603 | 272/595 |
| DIARRHOEAGastrointestinal disorders | 244/603 | 266/595 |
| PERIPHERAL SENSORY NEUROPATHYNervous system disorders | 64/603 | 258/595 |
| VOMITINGGastrointestinal disorders | 168/603 | 250/595 |
| ALOPECIASkin and subcutaneous tissue disorders | 20/603 | 245/595 |
| WEIGHT DECREASEDInvestigations | 104/603 | 194/595 |
| NAIL DISORDERSkin and subcutaneous tissue disorders | 77/603 | 193/595 |
| ANOREXIAMetabolism and nutrition disorders | 99/603 | 183/595 |
| Age, Customized(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| <65 years | 532 | 531 | 1063 |
| ≥65 years | 77 | 81 | 158 |
| <50 years | 225 | 235 | 460 |
| ≥50 years | 384 | 377 | 761 |
| Age, Continuous(years) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Median | 53.0 (23.0 to 78.0) | 53.0 (24.0 to 81.0) | 53.0 (23.0 to 81.0) |
| Sex: Female, Male(Participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Female | 609 | 612 | 1221 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 2 | 3 |
| Asian | 90 | 69 | 159 |
| Black or African American | 25 | 21 | 46 |
| White | 480 | 502 | 982 |
| Unknown or Not Reported | 13 | 18 | 31 |
| Karnofsky performance Status(units on a scale) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| 100 | 219 | 265 | 484 |
| 90 | 187 | 188 | 375 |
| 80 | 151 | 130 | 281 |
| 70 | 44 | 26 | 70 |
| <70 | 2 | 2 | 4 |
| not reported | 6 | 1 | 7 |
| Menopausal Status(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Premenopausal | 93 | 90 | 183 |
| Perimenopausal | 32 | 32 | 64 |
| Postmenopausal | 475 | 481 | 956 |
| Not Reported | 9 | 9 | 18 |
| Organ Sites(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Ascites | 13 | 16 | 29 |
| Bone | 283 | 287 | 570 |
| Brain | 0 | 1 | 1 |
| Breast | 41 | 54 | 95 |
| Chest Wall Mass | 47 | 38 | 85 |
| CNS | 1 | 0 | 1 |
| Cutaneous | 64 | 57 | 121 |
| Effusion | 7 | 7 | 14 |
| Intestine | 1 | 1 | 2 |
| Lymph Node | 236 | 233 | 469 |
| Mediastinum | 54 | 52 | 106 |
| Other | 17 | 30 | 47 |
| Pleura | 86 | 84 | 170 |
| Subcutaneous | 23 | 24 | 47 |
| Visceral, Liver | 273 | 276 | 549 |
| Visceral, Lung | 221 | 217 | 438 |
| Visceral, Other | 24 | 26 | 50 |
| Presence with at least 1 lesion(participants) | Ixabepilone + Capecitabine | Capecitabine | Total |
|---|---|---|---|
| Number | 606 | 612 | 1218 |
Showing the first 100 of 189 sites across 29 countries. Choose a country and city above to see the rest.
The record gives a start of Nov 2003, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2009, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ixabepilone · Capecitabine